BIOVIE INC.: directors' dealings · United States · SEC (Form 4)

About BIOVIE INC.

BioVie Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ Capital Market in the United States under the symbols BIVI and BIVIW. The company is headquartered in Carson City, Nevada, and is classified as a clinical-stage developer focused on innovative drug therapies for neurological and neurodegenerative disorders as well as advanced liver disease. BioVie was formerly known as NanoAntibiotics, Inc., a name change that reflected a strategic shift away from its earlier identity toward a more targeted life-sciences platform centered on inflammation-related disease pathways and unmet medical needs. BioVie’s business model is that of a clinical-stage biotech: it does not yet operate as a diversified commercial pharma company with meaningful marketed-product revenue. Instead, its value proposition rests on advancing investigational assets through preclinical and clinical development, then ultimately navigating regulatory review and commercialization. Its main asset is NE3107, also known by the approved generic name bezisterim, an orally administered small molecule being studied for its potential to modulate inflammation, insulin resistance, and inflammatory cascades implicated in neurodegenerative disease. In parallel, BioVie is developing programs in advanced liver disease, giving the company a dual-therapeutic focus that spans neurology and hepatology. From a competitive standpoint, BioVie operates in highly crowded and scientifically demanding markets. In neurodegeneration, it competes indirectly with large pharmaceutical companies, specialty biotechs, and research programs pursuing Alzheimer’s disease and related inflammatory mechanisms. In liver disease, it faces similarly intense competition from companies with deeper pipelines and larger balance sheets. BioVie’s differentiation lies in its mechanism-driven approach and in targeting diseases with substantial unmet need, but the company remains exposed to the standard biotech risks: clinical trial failure, regulatory setbacks, dilution risk, and ongoing capital requirements. Its geographic footprint is predominantly U.S.-based, with corporate and operational presence in Nevada, while the NASDAQ listing gives it access to U.S. capital markets and broader international investor visibility. Recent corporate developments underscore the company’s financing-heavy profile. In August 2025, BioVie completed a public offering of units and warrants that raised approximately $12 million, illustrating the company’s reliance on external capital to fund development and corporate operations. Recent SEC filings also indicate ongoing litigation-related disclosures tied to prior company communications and alleged misstatements concerning clinical programs and prospects. For investors in France, Belgium, and Switzerland, BioVie should therefore be viewed as a high-risk, event-driven biotech name whose valuation will likely depend on clinical readouts, financing discipline, and the company’s ability to advance bezisterim and its liver-disease programs without excessive dilution.